Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Quoin Pharmaceuticals

Tracked across 3 events · 19 articles · First seen Jul 09, 2026 · Last active Sep 08, 2026

Sentiment
40
Attention
2
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 10
Regulatory
Impact: Quoin Pharmaceuticals received FDA IND clearance for QRX003 in Peeling Skin Syndrome, enabling a Phase 2 study. The company's stock fell over 8% in pre-market trading, reflecting mixed market sentiment.
Jul 09, 2026 · 7 articles
2 40
Business
Impact: Quoin Pharmaceuticals is the issuer in this private placement, raising up to $50 million to fund operations and clinical development. The financing strengthens its balance sheet and extends its cash runway into 2029.
Aug 28, 2026 · 6 articles
2 70
Regulatory
On September 8, 2026, the U.S. United States — Food and Drug Administration granted Rare Pediatric Disease (RPD) Designation to Quoin Pharmaceuticals' lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). This is…
Impact: Quoin is the developer of QRX003 and the recipient of the RPD designation, which strengthens its pipeline and potential for PRV-derived value.
Sep 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Quoin Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.